tbuckley/cabot-search huggingface dataset:
293P Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population
Authors: A. Casadei Gardini, L. Fornaro, S. Lonardi, T. Satake, J. Lucchetti, L. Antonuzzo, J.W. Kim, T. Bekaii-Saab, I.G. Rapposelli, A. Boccaccino, F. Finkelmeier, G. Giordano, M. Niger, H.J. Chon, C. Braconi, D. López-Valbuena, G. Farinea, L. Rimassa, M. Rimini
Journal: Annals of Oncology (2024)
245P Neoadjuvant intensified chemotherapy vs standard therapy in locally advanced rectal cancer
Authors: R. Ambraziene, R. Malonyte, R. Muduraite, G. Chlebopaseviene, L. Jarusevicius, I. Pikuniene, T. Latkauskas, R. Janciauskiene
Journal: Annals of Oncology (2024)
220P Treatment outcomes of amrubicin monotherapy for patients with advanced hepatobiliary and pancreatic neuroendocrine carcinoma
Authors: K. Inoue, M. Sasaki, S. Yamaguchi, T. Taira, T. Shibuki, T. Satake, K. Watanabe, H. Imaoka, S. Mitsunaga, M. Ikeda
Journal: Annals of Oncology (2024)
291P Tumor biology, treatment patterns, and survival outcomes in young-onset biliary tract cancers
Authors: A. Turpin, T. Pudlarz, L. Antoun, N.S. Tissera Valencia, M. Hilmi, F. Castet, D. López-Valbuena, M. Delaye, A. Italiano, M. Valery, V. Boige, D. Malka, E. Garcia-Galea, G. Castillo, T. Tian, A. Hollebecque, C. Smolenschi, M.P. Ducreux, T. Macarulla Mercade, A. Boileve
Journal: Annals of Oncology (2024)
218P Systemic inflammatory index (SII) in neuroendocrine tumors (NETs) treated with peptide receptor radionuclide therapy (PRRT)
Authors: E. Terán Brage, E. Campaña-Díaz, M. Navarro Martín, P. García-Talavera, Á. López Gutiérrez, P. Reguera Puertas, S. Rama-Alonso, J. Roldan Ruiz, L. Posado Domínguez, E. Pablo Martín, R. Lozano Mejorada, E. Fonseca Sánchez
Journal: Annals of Oncology (2024)
249P The efficacy and safety of short-course radiotherapy followed by sequential chemotherapy and cadonilimab for locally advanced rectal cancer: The preliminary findings of prospective, multicenter phase II trial
Authors: L. Feng, Y. Tang, W. Zhang, T. Xu, H. Li, H. Ma, H. Zhou, W. Kang, W. Huang, S-M. Zou, Y. Chi, Y. Wang, F. Deng, L-M. Jiang, C. Hu, Y. Chen, J. Jin
Journal: Annals of Oncology (2024)
288P Recent advances in systemic therapy for advanced biliary tract cancer: A systematic review and meta-analysis
Authors: Z. Li, D. Aliseda, O. Jones, L. Rajendran, C.T.J. Magyar, R. Grant, G.M. O'Kane, A. Saborowski, A. Vogel, G. Sapisochin
Journal: Annals of Oncology (2024)
283P Postoperative adjuvant tislelizumab plus lenvatinib and capecitabine for biliary tract cancer: Interim results of a prospective, single-arm, phase II study
Authors: Y. Feng, N. Zhang, Y. Zhao, Q. Pan, A. Mao, W. Zhu, Z. Lin, L. Wang, Y.L. Wang, J. Zhou, T. Zhang, L. Wang
Journal: Annals of Oncology (2024)
250P Short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma: Final analysis of the phase II Averectal trial
Authors: L. Chehade, R. Turfa, J. Kattan, S. Temraz, Y. Zeidan, R. Amarin, T. Alawabdeh, S. Deeba, S. Doughan, I. Mohamad, M. Elkhaldi, F.S. Daoud, M. Almasri, A. Dabous, A. Hushki, M. Aldarazi, M. Charafeddine, F. Geara, A.I. Shamseddine
Journal: Annals of Oncology (2024)
407P Comprehensive assessment of actionable and druggable genomic alterations for young adults with esophageal squamous cell carcinoma based on the national cancer genome database in Japan
Authors: K. Shiraishi, S. Yamamoto, Y. Yoshinami, M. Itoyama, H. Imazeki, K. Yokoyama, Y. Honma, T. Kashihara, D. Kurita, K. Ishiyama, J. Oguma, H. Igaki, H. Daiko, K. Kato
Journal: Annals of Oncology (2024)
408P Retrospective analysis of concurrent chemoradiation with carboplatin/paclitaxel vs FOLFOX in esophageal adenocarcinoma
Authors: J.A. Adler, K. Patell, N. Naleid, R. Rao, M. Elshami, R. Patel, J. Kaur, G. Guzik, R. Karia, A. Mohamed, D. Bajor, M.L. Conces, M. Lumish, L. Ocuin, L. Henke, A. Mahipal, S. Chakrabarti, J.E.E. Selfridge
Journal: Annals of Oncology (2024)
398P Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Additional analysies from 45-month (mo) follow-up of CheckMate 648
Authors: A. Adenis, I. Chau, J.A. Ajani, Y. Kitagawa, J. Xu, L.S. Wyrwicz, S. Motoyama, T. Ogata, H. Kawakami, C-H. Hsu, F. El Hajbi, M. Di Bartolomeo, M.I. Braghiroli, E. Holtved, M. Blum Murphy, J. Zhang, N. Hu, Y. Matsumura, K. Kato, Y. Doki
Journal: Annals of Oncology (2024)
234P Do we need molecular profiling in patients with squamous anal carcinoma?
Authors: C. Smolenschi, R. Sharaf, A. Hollebecque, F. Facchinetti, F. Dallolio, K. Ouali, A. Italiano, A. Boileve, M. Valery, T. Pudlarz, A. Tarabay, V. Boige, A.C. Fuerea, M.P. Ducreux, B. Cheaib, J.E. Rodriguez, C.P. Massard, O. Gjoerup, A. Fine, D. Vasseur
Journal: Annals of Oncology (2024)
292P Extended molecular profiling (EMP) and access to targeted treatment (TT) in advanced biliary tract cancer (BTC): Results from the Italian cholangiocarcinoma dataset (ANITA)
Authors: V. Genovesi, M. Rimini, T. Pressiani, M.D. Rizzato, M. Niger, L. Salvatore, L. Antonuzzo, L. Silvestro, A. Diana, F. Leone, F. Salani, S. Foti, V. Zanuso, A. De Rosa, C.C. Pircher, C. Vivaldi, L. Rimassa, S. Sperotto, A. Casadei Gardini, L. Fornaro
Journal: Annals of Oncology (2024)
409P Investigation of synergistic effects in trials of combination therapies with immune-checkpoint inhibitors in advanced esophageal squamous cell carcinoma
Authors: J. Okui, K. Nagashima, S. Matsuda, Y. Sato, H. Kawakubo, M. Takeuchi, K. Hirata, S. Yamamoto, M. Nomura, T. Tsushima, H. Takeuchi, K. Kato, Y. Kitagawa
Journal: Annals of Oncology (2024)
297P Real-life efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient (dMMR/MSI-H) biliary tract cancer (BTC)
Authors: I. Campo le Brun, E. Grapinet, A. Hollebecque, V. Aurillac, P. Parent, P. Girot, M. Gendreau, S. Rafert, S. Javed, Y. Touchefeu, G. Roth, M. Muller, M. Lequoy, A. Boilève, M. Decraecker
Journal: Annals of Oncology (2024)
274P Utility of MRI-based radiomic metrics and circulating tumor DNA to predict outcomes in locally advanced rectal cancer
Authors: G. Marisi, C. Molinari, G. Feliciani, A.I. Prochowski, G. Laliotis, I.G. Rapposelli, E. Petracci, S. Sharma, P. Dutta, M. Malhotra, M.C. Liu, P. Ulivi, G.L. Frassineti, M. Murator, A. Romeo, A. Jurdi, G. Martinelli, A. Passardi
Journal: Annals of Oncology (2024)
227P Clinical outcomes and molecular characterization of appendiceal goblet cell adenocarcinoma in 414 patients
Authors: A. Yousef, M.M.G. Yousef, S. Chowdhury, Z. Alavi Naini, M.M. Fanaeian, M. Knafl, P. Roy, I. Ito, V. Pattalachinti, W. Foo, B. Kee, S. Kopetz, A. Uppal, M.G. White, B. Helmink, K. Fournier, K. Raghav, M. Taggart, M.J. Overman, J.P.Y-C. Shen
Journal: Annals of Oncology (2024)
242MO Neoadjuvant nivolumab plus ipilimumab in microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) rectal tumors: ECOG-ACRIN EA2201
Authors: K.K. Ciombor, S. Hong, C. Eng, X. Yao, N. You, P. Das, A. Chakravarthy, P.J. O'Dwyer
Journal: Annals of Oncology (2024)
251P Phase II study of organ preservation (OP) using neoadjuvant chemotherapy (Ctx) and local excision (LE) in node-negative (NN) low rectal cancer (RC)
Authors: V. Wookey, J. Farma, J. Meyer, E. Ross, T. Singh, R. Romasko, R. Veggeberg, E. Dotan, M.J. Hall, M. Philp, J. Mittal, K. Bynum, S. Greco, S. Reddy, E. Sigurdson, N. Vijayvergia
Journal: Annals of Oncology (2024)
264P Real-life data on the use of CRT and SCRT for patients with locally advanced rectal cancer
Authors: C. De Zea Luque, A.M. Martin Fernandez de Soignie, I. Solana Lopez, F. Escalona Martín, I. Santana Gómez, D. Gutierrez Abad, M.V. De Torres Olombrada, I. Juez, E. Martinez Moreno, J.A. Guerra Martínez, C. Pantin, L. Rodriguez Lajusticia, B. Losada Vila, R. Hernandez López, J. Calzas Rodriguez
Journal: Annals of Oncology (2024)
272P Outcomes with total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC) with poor response on interim MRI
Authors: Y. Bouferraa, X. Jia, D. Liska, S. Amarnath, S. Steele, E. Gorgun, A. Purysko, A. Khorana, S.D. Kamath, E. Balagamwala, S. Krishnamurthi
Journal: Annals of Oncology (2024)
247P Radiotherapy (RT), atezolizumab (atezo) and bevacizumab (bev) to increase organ preservation in rectal cancer: The TARZAN study
Authors: P.G.M. de Gooyer, Y.L. Verschoor, A.G. Aalbers, D.M.J. Lambregts, B. van Triest, F. Peters, M.E. van Leerdam, S. Dokter, G.L. Beets, I. Huibregtse, R.G. Beets-Tan, S. Balduzzi, B.A. Grotenhuis, J.G. van den Berg, M. Chalabi
Journal: Annals of Oncology (2024)
225P Nuclear exporter protein exportin 1 (XPO1) as a novel therapeutic target in pancreatic neuroendocrine tumors
Authors: A.S. Azmi, M.H. Uddin, S.F. Bannoura, H.M. Khan, M. Diab, S. Kim, E. Beal, M. Tobon, H. Chen, R. Beydoun, G. Dyson, R.M. Mohammad, P.A. Philip, M.N. Al-Hallak, B.F. El-Rayes, B. Pasche
Journal: Annals of Oncology (2024)
261P Evaluating tumor regression grade in locally advanced rectal cancer: Identifying predictive factors and clinical implications following neoadjuvant chemoradiotherapy
Authors: A. Jain, V. Goyal, S. Soni, S. Narayan, P. Redhu, S.S. Mathighatta Shivarudraiah, P. Goyal, S. Goyal, U. Batra, V. Talwar
Journal: Annals of Oncology (2024)
229P BISQUIT: A randomized phase II trial of Prebiotics and Probiotics (PreProbiotics) during chemoradiation (CRT) for patients (pts) with squamous cell carcinoma of the anal canal (SCCA)
Authors: R.S.P. Riechelmann, M. Camandaroba, V.S. E Silva, R. Gomes Taboada, L. Durant, T.C. Felismino, L. Debrot, S. Aguiar, L. Silva, E.N.P. Lima, A. Miguez, D. Carraro, E. Santos Neto, F. McAllister, T. Bartelli
Journal: Annals of Oncology (2024)
244P Phase II randomized multicentre study comparing neoadjuvant chemoradiotherapy followed by consolidation chemotherapy to neoadjuvant chemoradiotherapy alone in non-metastatic rectal cancer patients
Authors: S.A. Elsamany, A. Aljubran, H.M.A. El-Khatib, S. Elmorsy, F. Hassanin, A. Alsuhaibani, E. Tashkandy, S. Abdelkhalek, M. Algarni, S. Alzahrani, M. Yousef, M. Shouki Ahmad A Bazarbashi
Journal: Annals of Oncology (2024)
286P TQB3454 in mutant IDH1 advanced cholangiocarcinoma (CCA): Results of a phase I dose escalation and expansion study cohort
Authors: J. Yuan, Y. Zheng, L. Xu, F. Xie, S. Gu, Q. Li, J. Zhang, Y. Ba, D. Huaxin, A. Yang, J. Li, J. Zhou, L. Shen
Journal: Annals of Oncology (2024)
287P Association of progression-free survival (PFS) with overall survival (OS) in advanced biliary tract cancer (BTC): A trial- and patient-level analysis
Authors: F. Castet, C. Fabregat-Franco, J.W. Kim, M. Rimini, A. Lacasta, M. Kang, F. Salani, A.O. Castillo Trujillo, D.E. López Valbuena, M. Basagaña-Farrés, J.A. Adeva, A.J. Munoz Martin, J. Hyung, L. Rimassa, A. Casadei Gardini, C. Yoo, T. Macarulla Mercade
Journal: Annals of Oncology (2024)
282P Nivolumab and ipilimumab combination treatment in advanced intrahepatic cholangiocarcinoma and gallbladder cancer
Authors: O. Klein, M. Carlino, M. Brown, S.J. Harris, A. Gunjur, C.R. Underhill, R. Zielinski, D. Kee, W-S. Lam, H. Chan, R.A. Harrup, J. So, I. Collins, M. Michael, J. Torres, J.B. Palmer, D. Thomas, K. Wilkie, J. Cebon, A. Nagrial
Journal: Annals of Oncology (2024)
226P Risk of relapse following surgical resection of localized appendiceal adenocarcinoma
Authors: M.M. Fanaeian, M.M.G. Yousef, A. Yousef, M. Taggart, W. Foo, K. Beaty, C. Scally, P.F. Mansfield, K. Fournier, M.G. White, B. Helmink, J.P.Y-C. Shen
Journal: Annals of Oncology (2024)
285P Gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer: A multicenter, single-arm, phase I/II trial
Authors: T. Pressiani, R. Balsano, L. Giordano, M. Milella, F. Bergamo, S. Bozzarelli, S. Noventa, D. Ferrari, M. Scartozzi, H.J. Soto Parra, A. Auriemma, C. Soldà, A. Zaniboni, C. Zecchetto, M.D. Rizzato, L. Rimassa, A. Santoro
Journal: Annals of Oncology (2024)
280MO CD40 agonist mitazalimab combined with mFOLFIRINOX (mFFX) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Primary analysis of the OPTIMIZE-1 phase Ib/II study
Authors: T. Macarulla Mercade, I. Borbath, K. Geboes, A. Lambert, P. Cassier, H. Prenen, E. Mitry, J.F. Blanc, L. Pilla, J. Feliu, M. Rodriguez, R.A. Pazo Cid, I. Gallego Jimenez, D. Gomez Jimenez, K.E. Smith, K. Nordbladh, P. Ellmark, Y. Pico de Coaña, S.V. Ambarkhane, J-L. van Laethem
Journal: Annals of Oncology (2024)
302P A multicenter retrospective study of survival benefits of statins in unresectable or recurrent advanced biliary tract cancer patients
Authors: K. Tsugaru, Y. Maruki, T. Okamoto, N. Sasahira, K. Oshima, K. Ishigaki, M. Noguchi, R. Kizawa, R. Sawada, Y. Saito, K. Hirata
Journal: Annals of Oncology (2024)
243P Neoadjuvant XELOX chemotherapy with or without cadonilimab in locally advanced pMMR rectal cancer: Preliminary results from a randomized, open-label phase II trial
Authors: H. Zhou, C. Gong, J. Zhang, S. Zou, J. Tang, J. Liang, Z. Liu, W. Zhang, Z. Jiang, W. Qu, H. Zhang, Q. Zhao, Y. Sun, A. Zhou
Journal: Annals of Oncology (2024)
301P Homologous recombination repair (HRR) deficiency in biliary tract cancers: Clinical implications in subsequent therapy lines and correlation with platinum sensitivity
Authors: I. Mavroeidi, T.W. Seyed Mohammad, G. Webersinke, J. Burghofer, G. Piringer, S. Kasper-Virchow, S-T. Liffers, A. Reichinger, P. Kirchweger, S. Heibl, R.W. Hamacher, A.L. Petzer, M.H.H. Schuler, G. Prager, D.M. Kersting, J.W. Treckmann, H-U. Schildhaus, H. Rumpold, J.T. Siveke, B. Doleschal
Journal: Annals of Oncology (2024)
258P The impact of total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC): A real-world Italian multicentric experience
Authors: F. Lo Prinzi, V. Picone, F. Zoratto, E. Dell'Aquila, G. Caira, M. Veroli, G. Arrivi, A. Emiliani, M. Schirripa, R. Ajdhoni, E. Bengala, A. Spring, M.V. Bonomo, B. Di Cocco, C. Fiore, M.G. Polito, D. Giannarelli, A. Torsello
Journal: Annals of Oncology (2024)
401P Vibostolimab coformulated with pembrolizumab (vibo/pembro) + chemotherapy (chemo) as first-line treatment for advanced esophageal cancer (ec): Results from cohort E of the phase II KEYVIBE-005 study
Authors: C-H. Hsu, R. Dziadziuszko, D.A. Gomez Abreo, S. Aksoy, M. Gil Martín, C. Roderburg, C.J. Yen, A. Arican, P. Cassier, S-A. Im, S-B. Kim, T. Kudo, S. Ochsenreither, M.A.N. Sendur, K. Yonemori, C.I. Rojas, Q. Liu, T. Keenan, J. Healy, M. Kwiatkowski
Journal: Annals of Oncology (2024)
281P Comparison of efficacy &amp; safety of two frontline cytotoxic chemotherapy regimens in newly diagnosed metastatic cancer of biliary tract: A randomized control study
Authors: N. Sinha, A. Sehrawat, J. Porwal, D. Sundriyal, S. Gupta, U. Chauhan, A. Gupta
Journal: Annals of Oncology (2024)
253P International real-world study of total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC)
Authors: A. Audisio, V. Velenik, H. Meillat, E. Ruiz, M.C. Riesco Martinez, J. Suarez, J. Dekervel, C. Carvalho, V. Randrian, I. Kirac, J. Hernando Cubero, M. Artaç, J.M.R. O'Connor, I. Waldhorn, P. Braam, A.I. Shamseddine, E.D. Saad, V. Deltuvaite-Thomas, V. Staggs, F. Sclafani
Journal: Annals of Oncology (2024)
402P Long-term outcomes of dose-escalated proton beam therapy with concurrent chemotherapy in stage IB/II/III (non-T4) esophageal squamous cell carcinoma: A phase I study and its long-term outcomes
Authors: H. Hojo, T. Kojima, M. Nakamura, T. Fujisawa, H. Oyoshi, K. Tomizawa, Y. Zhou, K. Fukushi, S. Zenda, T. Akimoto
Journal: Annals of Oncology (2024)
221P TEMCAP regimen as first-line therapy in patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) at a Latin American reference center: A ten-year follow-up study
Authors: W.E. Cruz Diaz, V.R. Paitan Amaro, R. Flores, J. Medina, J.C. Haro Varas, J.G. Macetas, A.D. Leonardo Carbajal, E.C. Veramendi Cabana, C. Pacheco, M.J. Calderon Anticona, V. Castro Oliden
Journal: Annals of Oncology (2024)
236P Oncogenic fusions shape the landscape of actionable genomic alterations in pancreatic acinar cell carcinoma
Authors: S. Lange, E-M. Mayr, A. Jacob, K. Merkl, K. Utpatel, P. Bronsert, A. Baude, S. Chakraborty, A. Muckenhuber, M. Quante, R. Schmid, S. Fröhling, M. Evert, W. Weichert, N. Pfarr
Journal: Annals of Oncology (2024)
248P Preliminary results from CA209-8M4: A phase II trial evaluating the addition of nivolumab (nivo) to total neoadjuvant treatment (TNT) for locally advanced rectal cancer (LARC)
Authors: B. Brenner, G. Perl, A. Rosenberg Ayal, T. Shalmon, T. Shochat, A. Sulkes, H. Bernstine, I. White, N. Gurevich, Y. Feferman, N. Issa, N. Wasserberg, Y. Kundel
Journal: Annals of Oncology (2024)
219P Real-world efficacy and safety of peptide receptor radionuclide therapy (PRRT) with 177Lu-Dotatate (Lutathera) (LU) in neuroendocrine tumors (NETs)
Authors: M. Navarro Martín, E. Terán Brage, E. Campaña-Díaz, P. García-Talavera, P. Reguera Puertas, S. Rama-Alonso, M.C. Garijo-Martínez, L.C. Felix, P. Díaz Sánchez, R. Vidal Tocino, E. Fonseca Sánchez
Journal: Annals of Oncology (2024)
213P Clinical characteristics and treatment outcomes of primary hepatic neuroendocrine neoplasms (PHNEN)
Authors: L. Apostolidis, L. de Mestier du Bourg, Z. Kender, V. Flegka, E.C. Winkler, S. Krug, C. Kratochwil, O. Hentic Dhome, P. Ruszniewski, J. Cros, B. Goeppert, S. Roessler
Journal: Annals of Oncology (2024)
416P Evolutionary and immune microenvironment dynamics determine response to neoadjuvant treatment of oesophageal adenocarcinoma
Authors: M. Barroux, J. Househam, E. Lakatos, T. Ronel, A-M. Baker, H. Salié, M. Mossner, M. Jansen, G. Caravagna, K. Steiger, J. Slotta-Huspenina, W. Weichert, M. Alberstmeier, B. Chain, H. Friess, B. Bengsch, R. Schmid, J.T. Siveke, M. Quante, T. Graham
Journal: Annals of Oncology (2024)
397MO Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in HER2-negative advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GC/GEJC): PD-L1 biomarker analysis from RATIONALE-305
Authors: M. Moehler, D-Y. Oh, K. Kato, J. Tabernero, M. Cruz-Correa, L.S. Wyrwicz, R.A. Pazo Cid, A. Cubillo, L. Evesque, L. Fornaro, E. Dotan, C. Morgan, L. Li, Y. Xu, T. Sheng, S. Yang, H. Hu, R-H. Xu
Journal: Annals of Oncology (2024)
217P Less frequent radiological response assessment to reduce costs from 177-LuDOTATE therapy for patients with advanced neuroendocrine tumors
Authors: C.C. Marques, A.B. Carvalho De Brito, M.D. Spina Donadio, E.N.P. Lima, R.S.P. Riechelmann
Journal: Annals of Oncology (2024)
269P Neutrophil to lymphocyte ratio in locally advanced rectal cancer and prognosis of mortality in Mexican patients
Authors: A.W. Saenz Mamani, M.D.C. Diaz Romero, M. Ramirez, J. Cervantes Bojalil, V. Salais Michaus, M. Herrera, S.M. Miyagui Adame, G. Calderillo Ruiz, S. Zilli Hernández, J. Melchor-Ruan, E. Ruiz
Journal: Annals of Oncology (2024)
Study of the effect of magnetic fields on static degradation of Fe and Fe-12Mn-1.2C in balanced salts modified Hanks’ solution
Authors: Irene Limón, Marta Multigner, Carlo Paternoster, Marcela Lieblich, Belén Torres, Diego Mantovani, Joaquín Rams
Journal: Bioactive Materials (2024)

Iron and its alloys are attractive as biodegradable materials because of their low toxicity and suitable mechanical properties; however, they generally have a slow degradation rate. Given that corrosion is an electrochemical phenomenon where an exchange of electrons takes place, the application of magnetic fields from outside the body may accelerate the degradation of a ferrous temporary implant. In the present study, we have investigated the effect of alternating and direct low magnetic field (H = 6.5 kA/m) on the corrosion process of pure iron (Fe) and an iron-manganese alloy (FeMnC) in modified Hanks' solution. A 14-day static immersion test was performed on the materials. The corrosion rate was assessed by mass and cross-sectional loss measurements, scanning electron microscopy, X-ray diffractometry, Fourier-transform infrared spectroscopy and X-ray photoelectron spectroscopy before and after degradation. The results show that the presence of magnetic fields significantly accelerates the degradation rate of both materials, with the corrosion rate being twice as high in the case of Fe and almost three times as high for FeMnC. In addition, a homogenous degradation layer is formed over the entire surface and the chemical composition of the degradation products is the same regardless of the presence of a magnetic field.
Additive manufacturing of degradable metallic scaffolds for material-structure-driven diabetic maxillofacial bone regeneration
Authors: Wencheng Song, Danlei Zhao, Fengyuan Guo, Jiajia Wang, Yifan Wang, Xinyuan Wang, Zhengshuo Han, Wenjie Fan, Yijun Liu, Zhi Xu, Lili Chen
Journal: Bioactive Materials (2024)

The regeneration of maxillofacial bone defects associated with diabetes mellitus remains challenging due to the occlusal loading and hyperglycemia microenvironment. Herein, we propose a material-structure-driven strategy through the additive manufacturing of degradable Zn–Mg–Cu gradient scaffolds. The in situ alloying of Mg and Cu endows Zn alloy with admirable compressive strength for mechanical support and uniform degradation mode for preventing localized rupture. The scaffolds manifest favorable antibacterial, angiogenic, and osteogenic modulation capacity in mimicked hyperglycemic microenvironment, and Mg and Cu promote osteogenic differentiation in the early and late stages, respectively. In addition, the scaffolds expedite diabetic maxillofacial bone ingrowth and regeneration by combining the metabolic regulation effect of divalent metal cations and the hyperboloid and suitable permeability of the gradient structure. RNA sequencing further reveals that RAC1 might be involved in bone formation by regulating the transport and uptake of glucose related to GLUT1 in osteoblasts, contributing to cell function recovery. Inspired by bone healing and structural cues, this study offers an essential understanding of the designation and underlying mechanisms of the material-structure-driven strategy for diabetic maxillofacial bone regeneration.